Innate Pharma Files 6-K Report
Ticker: IPHA · Form: 6-K · Filed: Apr 8, 2026 · CIK: 0001598599
Sentiment: neutral
Topics: regulatory-filing, foreign-issuer
TL;DR
Innate Pharma filed a 6-K on 4/8/26. Standard foreign issuer report.
AI Summary
Innate Pharma SA filed a Form 6-K on April 8, 2026. This report is for a foreign issuer and includes documents such as the 6-K itself and Exhibit 99.1. The filing details Innate Pharma's mailing and business addresses in Marseille, France.
Why It Matters
This filing indicates ongoing reporting activity for Innate Pharma SA, a foreign issuer, which is important for investors tracking the company's regulatory compliance.
Risk Assessment
Risk Level: low — This is a routine foreign issuer filing (6-K) and does not appear to contain material new information or significant financial events.
Key Players & Entities
- Innate Pharma SA (company) — Filer of the 6-K report
- 0001598599 (company) — CIK number for Innate Pharma SA
- 2026-04-08 (date) — Filing date and period of report
FAQ
What type of filing is this 6-K for Innate Pharma SA?
This is a Form 6-K, which is a report of a foreign issuer.
When was this 6-K filing accepted by the SEC?
The filing was accepted on April 8, 2026.
What are the business and mailing addresses provided for Innate Pharma SA?
Both the business and mailing addresses are listed as 117 AVENUE DE LUMINY BP 30191 MARSEILLE FRANCE.
What is the CIK number associated with Innate Pharma SA?
The CIK number for Innate Pharma SA is 0001598599.
What SIC code is listed for Innate Pharma SA?
The SIC code listed is 2836 for Biological Products, (No Diagnostic Substances).
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on April 8, 2026 regarding Innate Pharma SA (IPHA).